Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate

被引：25
作者：
Poggio, F. [1 ]
Tagliamento, M. [2 ,3 ]
Ceppi, M. [4 ]
Bruzzone, M. [4 ]
Conte, B. [1 ,2 ]
Fregatti, P. [5 ,6 ]
Punie, K. [7 ,8 ]
de Azambuja, E. [9 ]
Del Mastro, L. [2 ,10 ]
Lambertini, M. [2 ,11 ]
机构：
[1] IRCCS Osped Policlin San Martino, Oncol Med 2, Genoa, Italy
[2] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Genoa, Italy
[3] Gustave Roussy, Dept Canc Med, Villejuif, France
[4] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Genoa, Italy
[5] IRCCS Osped Policlin San Martino, Dept Surg, UOC Clin Chirurg Senol, Genoa, Italy
[6] Univ Genoa, Sch Med, Dept Integrated Diagnost Surg Sci, Genoa, Italy
[7] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium
[8] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium
[9] Univ Libre Bruxelles ULB, Inst Jules Bordet, Brussels, Belgium
[10] IRCCS Osped Policlin San Martino, Breast Unit, Genoa, Italy
[11] IRCCS Osped Policlin San Martino, Dept Med Oncol, UOC Clin Oncol Med, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 03期
关键词：
D O I：
10.1016/j.annonc.2021.11.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：347 / 349
页数：3
相关论文
共 5 条
  • [1] Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    Korde, Larissa A.
    Somerfield, Mark R.
    Carey, Lisa A.
    Crews, Jennie R.
    Denduluri, Neelima
    Hwang, E. Shelley
    Khan, Seema A.
    Loibl, Sibylle
    Morris, Elizabeth A.
    Perez, Alejandra
    Regan, Meredith M.
    Spears, Patricia A.
    Sudheendra, Preeti K.
    Symmans, W. Fraser
    Yung, Rachel L.
    Harvey, Brittany E.
    Hershman, Dawn L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1485 - +
  • [2] Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
    Loibl, S.
    Sikov, W.
    Huober, J.
    Rugo, H. S.
    Wolmark, N.
    O'Shaughnessy, J.
    Maag, D.
    Untch, M.
    Golshan, M.
    Ponce Lorenzo, J.
    Metzger, O.
    Dunbar, M.
    Symmans, W. F.
    Geyer, C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S408 - S408
  • [3] Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
    Poggio, F.
    Bruzzone, M.
    Ceppi, M.
    Ponde, N. F.
    La Valle, G.
    Del Mastro, L.
    de Azambuja, E.
    Lambertini, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (07) : 1497 - 1508
  • [4] KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
    Schmid, P.
    Cortes, J.
    Dent, R.
    Pusztai, L.
    McArthur, H.
    Kummel, S.
    Bergh, J.
    Denkert, C.
    Park, Y. H.
    Hui, R.
    Harbeck, N.
    Takahashi, M.
    Untch, M.
    Fasching, P. A.
    Cardoso, F.
    Ding, Y.
    Tryfonidis, K.
    Aktan, G.
    Karantza, V.
    O'Shaughnessy, J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (09) : 1198 - 1200
  • [5] A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer
    Wu, Xiujuan
    Tang, Peng
    Li, Shifei
    Wang, Shushu
    Liang, Yueyang
    Zhong, Ling
    Ren, Lin
    Zhang, Ting
    Zhang, Yi
    [J]. NATURE COMMUNICATIONS, 2018, 9
1